Good morning, everyone, and welcome to another working week. We hope the weekend was relaxing and invigorating. Now, though, that familiar routine of meetings and deadlines has returned. We share your concerns, of course, and to cope with the mountain of to-do items, we are brewing a nice cup of stimulation. Our flavor is, once again, Southern Pecan. Please join us, or grab a bottle of water, if you prefer. Meanwhile, here are a few tidbits to help you get going. We hope your day goes well and do stay in touch...
China To Double Price-Controlled Drug List By Year End (Reuters)
Sandoz Shuts API Unit In India (Business Standard)
31 Drugs Facing FDA Approval in 2012 And 2013 (The Street)
US Panel May Make HIV Testing Routine (Reuters)
India To Introduce Pharma Marketing Code (Hindu Business Line)
FDA OKs BI & Lilly Tradjenta As Insulin Add-On (Pharma Times)
Vivus Stock Falls After Analyst Slashes Diet Pill Forecast (Associated Press)
Organoid Seen Cutting Drug Cost With Lab Mini-Intestine (Bloomberg News)
Ranbaxy Launches Authorized Generic Actos In US (Economic Times)
Cambrex Charles City To Expand And Add Jobs (Cedar Valley Business Journal)
Private Equity Firms Buys Mercury Pharma (Pharma Biz)
United Drug To Acquire Bilcare GCS (Irish Times)
EDITOR'S NOTE: Please check this post for updates during the day
sunrise pic thx to benimoto on flickr